AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3046747 — intervention group
Group type: EXPERIMENTAL
Intervention: GL enzyme (hyaglosidase)
Number of subjects: 1488
Study 3046747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1488
Study 1882908 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate 2 g, twice daily (b.i.d. group)
Number of subjects: 57
Study 1882908 — intervention group
Group type: COMPARATOR
Intervention: Sucralfate 1 g, four times daily (q.i.d. group)
Number of subjects: 57
Study 786314 — intervention group
Group type: EXPERIMENTAL
Intervention: Viloxazine (150-300 mg/day)
Number of subjects: 50
Study 786314 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 50
Study 30288563 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral isotretinoin (0.5 mg/kg) started on the 31st day after surgery, given every other day for 1 month and then daily for two additional months
Number of subjects: 48
Study 30288563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 27432355 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI measures of synovitis
Number of subjects: 291
Study 27432355 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI measures of osteitis
Number of subjects: 291
Study 27432355 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI measures of bone erosion
Number of subjects: 291
Study 27432355 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvements in synovitis and bone erosion
Number of subjects: 291
Study 27432355 — intervention group
Group type: EXPERIMENTAL
Intervention: Less improvement in synovitis and progression in MRI erosion at 52 weeks
Number of subjects: 291
Study 27432355 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression on X-ray
Number of subjects: 291
Study 26490434 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing LMWH treatment for CAT
Number of subjects: 32
Study 26490434 — intervention group
Group type: COMPARATOR
Intervention: Cessation of LMWH at 6 months' treatment
Number of subjects: 32
Study 24111502 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 LCPUFA supplementation (fish oil capsules providing 900 mg daily)
Number of subjects: 706
Study 24111502 — intervention group
Group type: COMPARATOR
Intervention: Control (matched vegetable oil capsules without n‐3 LCPUFA)
Number of subjects: 706
Study 24111502 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 LCPUFA supplementation (fish oil capsules)
Number of subjects: 706
Study 24111502 — intervention group
Group type: COMPARATOR
Intervention: Control (matched vegetable oil capsules)
Number of subjects: 706
Study 21375382 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty (PV)
Number of subjects: 82
Study 21375382 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy (OMT)
Number of subjects: 82
Study 18786624 — intervention group
Group type: EXPERIMENTAL
Intervention: UDB 0.06 mg
Number of subjects: 16
Study 18786624 — intervention group
Group type: EXPERIMENTAL
Intervention: UDB 0.12 mg
Number of subjects: 16
Study 18786624 — intervention group
Group type: EXPERIMENTAL
Intervention: UDB 0.24 mg
Number of subjects: 16
Study 18786624 — intervention group
Group type: COMPARATOR
Intervention: Commercial budesonide 0.25 mg
Number of subjects: 16
Study 17530263 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic colorectal resection
Number of subjects: 28
Study 17530263 — intervention group
Group type: COMPARATOR
Intervention: Conventional colorectal resection
Number of subjects: 28
Study 17530263 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall morbidity
Number of subjects: 28
Study 17530263 — intervention group
Group type: EXPERIMENTAL
Intervention: Local morbidity
Number of subjects: 28
Study 17530263 — intervention group
Group type: COMPARATOR
Intervention: High-quality RCT (E & P > 70)
Number of subjects: 28
Study 15791100 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (100 mg/kg before incision and 10 mg/kg/h during surgery)
Number of subjects: 44
Study 15791100 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (placebo)
Number of subjects: 44
Study 15791100 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 44
Study 11809113 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (0.1 mg IV injection + continuous drip at 25 microg/h for 24 hours)
Number of subjects: 24
Study 11809113 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (0.1 mg IV injection + continuous drip at 42 microg/h for 24 hours)
Number of subjects: 24
Study 11809113 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (40 mg IV injection + continuous drip at 8 mg/h for 24 hours)
Number of subjects: 24
Study 11809113 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (same dosage as in group 1 for 72 hours)
Number of subjects: 24
Study 11809113 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (same dosage as in group 3 for 72 hours)
Number of subjects: 24
Study 9275134 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory function evaluation using a modified Connecticut Chemosensory Clinical Research Center testing procedure for threshold, identification, and discrimination
Number of subjects: 17
Study 9275134 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal eosinophilic inflammation measured by eosinophil cationic protein (ECP) in nasal secretions
Number of subjects: 17
Study 9275134 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal volume flow (NVF) measurement
Number of subjects: 17
Study 9275134 — intervention group
Group type: COMPARATOR
Intervention: Control group (12 volunteers without allergy)
Number of subjects: 17
Study 7936562 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (trabeculectomy)
Number of subjects: 168
Study 7936562 — intervention group
Group type: COMPARATOR
Intervention: Medicine
Number of subjects: 168
Study 7936562 — intervention group
Group type: COMPARATOR
Intervention: Laser
Number of subjects: 168
Study 2896866 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous desferrioxamine 1 g at the end of each dialysis for six months
Number of subjects: 16
Study 2896866 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 16
Study 31648655 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 56
Study 31648655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 29644465 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentored group (one-to-one tutoring)
Number of subjects: 60
Study 29644465 — intervention group
Group type: COMPARATOR
Intervention: Control group (video material from SAGES)
Number of subjects: 60
Study 28814805 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercalating gefitinib (250 mg/day on days 15-25 of each cycle until disease progression)
Number of subjects: 219
Study 28814805 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (gemcitabine 1250 mg/m2 plus carboplatin 5 AUC)
Number of subjects: 219
Study 26598478 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine 2.5 mg b.i.d.
Number of subjects: 403
Study 26598478 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine 5 mg b.i.d.
Number of subjects: 403
Study 26598478 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine 10 mg b.i.d.
Number of subjects: 403
Study 26598478 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine (all doses)
Number of subjects: 403
Study 26598478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 403
Study 23578031 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI) 100/25 μg
Number of subjects: 185
Study 23578031 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI) 200/25 μg
Number of subjects: 185
Study 23578031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study 23578031 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone 10 mg daily
Number of subjects: 185
Study 22089446 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein (HP) diet
Number of subjects: 0
Study 22089446 — intervention group
Group type: COMPARATOR
Intervention: Lower protein (LP) diet
Number of subjects: 0
Study 19692802 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroperatively applied local doses of a mix containing corticosteroids
Number of subjects: 200
Study 19692802 — intervention group
Group type: COMPARATOR
Intervention: No corticosteroid treatment (control group)
Number of subjects: 200
Study 19692802 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (steroid and control)
Number of subjects: 200
Study 16987866 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine monotherapy (100 mg per day for 48 weeks)
Number of subjects: 162
Study 16987866 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential treatment with lamivudine (100 mg per day for 20 weeks) followed by interferon‐alpha‐2b (5 million units three times per week for 4 weeks, then 5 million units three times per week for another 24 weeks)
Number of subjects: 162
Study 16987866 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine monotherapy
Number of subjects: 162
Study 16987866 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential treatment
Number of subjects: 162
Study 15454274 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark chocolate (DC group)
Number of subjects: 45
Study 15454274 — intervention group
Group type: EXPERIMENTAL
Intervention: High-polyphenol chocolate (HPC group)
Number of subjects: 45
Study 15454274 — intervention group
Group type: COMPARATOR
Intervention: White chocolate (WC group)
Number of subjects: 45
Study 15454274 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (DC, HPC, WC)
Number of subjects: 45
Study 10927061 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified hysterosalpingography (1-2 mL of water-soluble contrast medium followed by 10 mL of saline)
Number of subjects: 78
Study 10927061 — intervention group
Group type: COMPARATOR
Intervention: Standard hysterosalpingography (undiluted contrast medium)
Number of subjects: 78
Study 8829934 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia (TIVA) with a propofol and alfentanil mixture
Number of subjects: 30
Study 8829934 — intervention group
Group type: COMPARATOR
Intervention: Standard inhalational technique
Number of subjects: 30
Study 2003707 — intervention group
Group type: COMPARATOR
Intervention: Single cycle of perioperative chemotherapy (cyclophosphamide, methotrexate, fluorouracil, leucovorin)
Number of subjects: 1229
Study 2003707 — intervention group
Group type: EXPERIMENTAL
Intervention: Six cycles of conventionally timed chemotherapy (cyclophosphamide, methotrexate, fluorouracil, prednisone) for premenopausal women or this combination plus tamoxifen for postmenopausal women
Number of subjects: 1229
Study 2003707 — intervention group
Group type: EXPERIMENTAL
Intervention: Both perioperative and conventionally timed chemotherapy for a 7-month course of adjuvant therapy
Number of subjects: 1229
Study 6391232 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 100
Study 6391232 — intervention group
Group type: COMPARATOR
Intervention: Antacid
Number of subjects: 100
Study 28815316 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 147
Study 28815316 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 147
Study 28815316 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline QoL factors
Number of subjects: 147
Study 27388365 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately unhealthy oral conditions based on OHAT scores
Number of subjects: 162
Study 27388365 — intervention group
Group type: EXPERIMENTAL
Intervention: Unhealthy oral conditions based on OHAT scores
Number of subjects: 162
Study 27388365 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-very poor oral hygiene assessed by PI
Number of subjects: 162
Study 27388365 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall oral health status
Number of subjects: 162
Study 27388365 — intervention group
Group type: EXPERIMENTAL
Intervention: VAP incidence
Number of subjects: 162
Study 27388365 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of teeth
Number of subjects: 162
Study 25961461 — intervention group
Group type: COMPARATOR
Intervention: 100 mg anacetrapib with background treatment of placebo
Number of subjects: 39
Study 25961461 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg anacetrapib with background treatment of 20 mg atorvastatin
Number of subjects: 39
Study 23986331 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling/root planing with Perioscope™
Number of subjects: 30
Study 23986331 — intervention group
Group type: COMPARATOR
Intervention: Scaling/root planing without Perioscope™
Number of subjects: 30
Study 20402755 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐Hz ipsi‐lesional rTMS
Number of subjects: 60
Study 20402755 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐Hz contra‐lesional rTMS
Number of subjects: 60
Study 20402755 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 60
Study 18628448 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted design randomizing patients with appropriate marker status
Number of subjects: 0
Study 18628448 — intervention group
Group type: COMPARATOR
Intervention: Randomizing all patients regardless of marker values
Number of subjects: 0
Study 16001165 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vinorelbine 70 mg/m2
Number of subjects: 27
Study 16001165 — intervention group
Group type: COMPARATOR
Intervention: Intravenous vinorelbine 30 mg/m2
Number of subjects: 27
Study 12581972 — intervention group
Group type: COMPARATOR
Intervention: 2.0 mg/ml ropivacaine (group R)
Number of subjects: 60
Study 12581972 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg/ml ropivacaine plus 1.0 microg/ml fentanyl (group RF1)
Number of subjects: 60
Study 12581972 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/ml ropivacaine plus 2.0 microg/ml fentanyl (group RF2)
Number of subjects: 60
Study 12581972 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/ml ropivacaine plus 4.0 microg/ml fentanyl (group RF4)
Number of subjects: 60
Study 10102744 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabers probe
Number of subjects: 10
Study 10102744 — intervention group
Group type: COMPARATOR
Intervention: Pressure‐calibrated plastic probe (TPS)
Number of subjects: 10
Study 7776420 — intervention group
Group type: EXPERIMENTAL
Intervention: Rufloxacin 200 mg once daily (after a loading dose of 400 mg on day 1)
Number of subjects: 110
Study 7776420 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 500 mg twice daily
Number of subjects: 110
Study 2149210 — intervention group
Group type: EXPERIMENTAL
Intervention: Calisthenics program (CAL) for 3 months with biweekly sessions of flexion exercises
Number of subjects: 142
Study 2149210 — intervention group
Group type: EXPERIMENTAL
Intervention: Back school program (5 sessions)
Number of subjects: 142
Study 2149210 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 142
Study 388407 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing 100 ppm of carbon monoxide (mean venous carboxyhemoglobin level raised from 1.42 to 3.90%)
Number of subjects: 20
Study 388407 — intervention group
Group type: COMPARATOR
Intervention: Compressed, purified air (mean carboxyhemoglobin level decreased from 1.43 to 1.26%)
Number of subjects: 20
Study 30298757 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive nonverbal feedback
Number of subjects: 130
Study 30298757 — intervention group
Group type: COMPARATOR
Intervention: Negative nonverbal feedback
Number of subjects: 130
Study 26522053 — intervention group
Group type: EXPERIMENTAL
Intervention: MTD doxorubicin (MTD-DOX)
Number of subjects: 0
Study 26522053 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination DOX/mCTX
Number of subjects: 0
Study 26522053 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent DOX
Number of subjects: 0
Study 26522053 — intervention group
Group type: COMPARATOR
Intervention: Control group (dogs receiving DOX alone)
Number of subjects: 0
Study 25873274 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertebroplasty
Number of subjects: 0
Study 25873274 — intervention group
Group type: COMPARATOR
Intervention: Placebo procedure
Number of subjects: 0
Study 24013941 — intervention group
Group type: EXPERIMENTAL
Intervention: BFRT low volume (BFRT LV)
Number of subjects: 35
Study 24013941 — intervention group
Group type: EXPERIMENTAL
Intervention: BFRT high volume (BFRT HV)
Number of subjects: 35
Study 24013941 — intervention group
Group type: COMPARATOR
Intervention: HIT
Number of subjects: 35
Study 21342768 — intervention group
Group type: EXPERIMENTAL
Intervention: Papillary muscle approximation (PMA) combined with ventriculoplasty
Number of subjects: 30
Study 21342768 — intervention group
Group type: COMPARATOR
Intervention: Control group (ventriculoplasty without PMA)
Number of subjects: 30
Study 19728220 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week home-based exercise program
Number of subjects: 88
Study 19728220 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 88
Study 17584355 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse's education using short message service (SMS) for 12 weeks, including diet, exercise, medication adjustment, and self-monitoring of blood glucose levels.
Number of subjects: 51
Study 17584355 — intervention group
Group type: COMPARATOR
Intervention: Nurse's education using short message service (SMS) for 12 weeks.
Number of subjects: 51
Study 15189746 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem 125 mg/h
Number of subjects: 7
Study 15189746 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem 250 mg/h
Number of subjects: 7
Study 15189746 — intervention group
Group type: COMPARATOR
Intervention: Meropenem 125 mg/h and 250 mg/h
Number of subjects: 7
Study 15189746 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem continuous infusion
Number of subjects: 7
Study 11245536 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet inflated at high pressure (about 350 mmHg)
Number of subjects: 31
Study 11245536 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet inflated at low pressure (about 225 mmHg)
Number of subjects: 31
Study 11245536 — intervention group
Group type: COMPARATOR
Intervention: No tourniquet
Number of subjects: 31
Study 9605374 — intervention group
Group type: EXPERIMENTAL
Intervention: MNS technique (4 injections of 10 mL each)
Number of subjects: 100
Study 9605374 — intervention group
Group type: COMPARATOR
Intervention: TA technique (2 injections of 20 mL each)
Number of subjects: 100
Study 8986187 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer's solution
Number of subjects: 0
Study 8986187 — intervention group
Group type: COMPARATOR
Intervention: Haemaccel
Number of subjects: 0
Study 2258780 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive drugs
Number of subjects: 0
Study 2258780 — intervention group
Group type: COMPARATOR
Intervention: Placebo phases
Number of subjects: 0
Study 2258780 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment phases
Number of subjects: 0
Study 7374099 — intervention group
Group type: COMPARATOR
Intervention: Isotonic electrolyte solution (control)
Number of subjects: 83
Study 7374099 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisacodyl
Number of subjects: 83
Study 7374099 — intervention group
Group type: EXPERIMENTAL
Intervention: Deoxycholic acid (high concentration)
Number of subjects: 83
Study 7374099 — intervention group
Group type: EXPERIMENTAL
Intervention: Meproscillarin
Number of subjects: 83
Study 7374099 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitoxin
Number of subjects: 83
Study 7374099 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 83
Study 7374099 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhein
Number of subjects: 83
Study 7374099 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholic acid
Number of subjects: 83
Study 7374099 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleic acid
Number of subjects: 83
Study 7374099 — intervention group
Group type: EXPERIMENTAL
Intervention: Ricinoleic acid
Number of subjects: 83
Study 30551540 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical emulgel formulation with Mimosa pudica seed extract
Number of subjects: 0
Study 30551540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29020976 — intervention group
Group type: EXPERIMENTAL
Intervention: Supporting LIFE electronic Community Case Management Application (SL eCCM App)
Number of subjects: 102
Study 29020976 — intervention group
Group type: COMPARATOR
Intervention: Paper-based Community Case Management (paper-CCM)
Number of subjects: 102
Study 26231464 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterus transplantation (UTx)
Number of subjects: 9
Study 23607537 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard behavioural weight loss programme (BWLP)
Number of subjects: 52
Study 23607537 — intervention group
Group type: COMPARATOR
Intervention: Stepped-down approach
Number of subjects: 52
Study 23607537 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater self-monitoring
Number of subjects: 52
Study 20950166 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (20 μg daily injections)
Number of subjects: 40
Study 20950166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 18769244 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern trial methodology and appropriate outcome measurements
Number of subjects: 0
Study 16365057 — intervention group
Group type: EXPERIMENTAL
Intervention: Tempeh (mainly isoflavone aglycon)
Number of subjects: 59
Study 16365057 — intervention group
Group type: COMPARATOR
Intervention: Textured vegetable protein (predominantly isoflavone glucosides)
Number of subjects: 59
Study 16365057 — intervention group
Group type: COMPARATOR
Intervention: Soy milk
Number of subjects: 59
Study 14616834 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with RAS
Number of subjects: 22
Study 14616834 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 22
Study 11027753 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic debridement and fenestration of the olecranon fossa
Number of subjects: 44
Study 11027753 — intervention group
Group type: EXPERIMENTAL
Intervention: O-K procedure
Number of subjects: 44
Study 11027753 — intervention group
Group type: COMPARATOR
Intervention: Both procedures
Number of subjects: 44